These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 3855615)

  • 21. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M; Metzger U; Joller H; Largiadèr F
    Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pancreatic oncofetal antigen (POA) and carcinoma of the pancreas].
    Homma T; Oguchi H; Kawa S; Nagata A; Furuta S
    Gan No Rinsho; 1984 May; 30(6 Suppl):558-62. PubMed ID: 6205174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
    Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pancreatic oncofetal antigen (POA): its characterization and application for enzyme immunoassay.
    Oguchi H; Homma T; Kawa S; Nagata A; Furuta S; Fukui H
    Cancer Detect Prev; 1984; 7(1):51-8. PubMed ID: 6367984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
    Takami H; Furuuchi T; Ogata Y; Abe O
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical evaluation of tumor markers in breast cancer patients].
    Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
    Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
    Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
    Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
    Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
    Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
    Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
    Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
    Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
    Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R; Kaesemann H; Caffier H
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
    Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
    Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies on serum CEA levels measured by enzyme immunoassay using monoclonal CEA-antibodies].
    Takada S; Hoshi H; Ito F; Imai K; Yachi A
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1487-91. PubMed ID: 6378102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.